European multicenter network to evaluate pharmacokinetics, safety and efficacy of Meropenem in neonatal sepsis and meningitis (NeoMero, 2010-2014) was funded by the European Commission under the Seventh Framework Programme and coordinated by Penta.
The project involved 12 partners from 8 European countries, with the main objective to compare the efficacy of meropenem to standard of care treatment of clinical or culture confirmed late-onset sepsis or meningitis. NeoMero core activities were carried out in two clinical trials designed to evaluate the pharmacokinetics, safety and efficacy of meropenem in neonates and infants younger than 3 months of age.
NeoMero publications:
- Soeorg H, Padari H, Ilmoja ML, et al. Prediction of C-reactive protein dynamics during meropenem treatment in neonates and infants. Br J Clin Pharmacol. 2024;90(3):801-811. doi:10.1111/bcp.15950
- Ciesielski TH, Zhang X, Tacconelli A, et al. Late-onset neonatal sepsis: genetic differences by sex and involvement of the NOTCH pathway. Pediatr Res. 2023;93(4):1085-1095. doi:10.1038/s41390-022-02114-8
- Lutsar I, Chazallon C, Trafojer U, et al. Meropenem vs standard of care for treatment of neonatal late onset sepsis (NeoMero1): A randomised controlled trial. PLoS One. 2020;15(3):e0229380. Published 2020 Mar 4. doi:10.1371/journal.pone.0229380
- Germovsek E, Lutsar I, Kipper K, et al. Plasma and CSF pharmacokinetics of meropenem in neonates and young infants: results from the NeoMero studies. J Antimicrob Chemother. 2018;73(7):1908-1916. doi:10.1093/jac/dky128
- Lutsar I, Chazallon C, Carducci FI, et al. Current management of late onset neonatal bacterial sepsis in five European countries. Eur J Pediatr. 2014;173(8):997-1004. doi:10.1007/s00431-014-2279-5
- Lutsar I, Trafojer UM, Heath PT, et al. Meropenem vs standard of care for treatment of late onset sepsis in children of less than 90 days of age: study protocol for a randomised controlled trial. Trials. 2011;12:215. Published 2011 Sep 30. doi:10.1186/1745-6215-12-215
